Press release
Rhinitis Pipeline 2025: Innovative Clinical Breakthroughs Led by 35+ Global Leaders, DelveInsight | Highlighting Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Abdi Ibrahim Pharma
Rhinitis Pipeline 2025
Rhinitis companies are Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma, AOBiome, Sanofi, Hanmi Pharmaceutical, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha Pharm, Siolta Therapeutics, Revelation Biosciences, Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology, Biomay AG, and others.
The rhinitis treatment market is being propelled by factors such as rising prevalence, advancements in therapeutic approaches, increased awareness, and the continuous development of novel drugs. According to DelveInsight, more than 35 pharmaceutical and biotech companies are actively pursuing over 35 therapeutic candidates for rhinitis, spanning multiple stages of clinical and preclinical development. This reflects strong innovation and dedication toward addressing a significant public health concern.
DelveInsight's "Rhinitis Pipeline Insight 2025" report offers a comprehensive and strategic assessment of the current R&D landscape. It explores clinical trial progress, emerging drug candidates, mechanisms of action, competitive dynamics, and major corporate initiatives. Serving as an essential resource, the report provides valuable insights for stakeholders-including researchers, healthcare investors, and decision-makers-into the evolving rhinitis therapeutics market and the scientific advancements shaping its future.
Explore the Cutting-Edge Landscape of Rhinitis Drug Development @ https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Rhinitis Pipeline Report
*
DelveInsight's Rhinitis pipeline report highlights a dynamic landscape with over 35 active companies developing more than 35 therapeutic candidates for rhinitis treatment.
*
In March 2025, the FDA approved Astepro (Azelastine Hydrochloride) nasal spray for over-the-counter use, marking it as the first nasal antihistamine available without a prescription for seasonal and perennial allergic rhinitis in adults and children aged 6 and above. Earlier, in August 2024, the FDA approved Neffy, an epinephrine nasal spray, offering a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis. Meanwhile, the FDA is reviewing the efficacy of oral phenylephrine, a widely used decongestant, and may remove it from the market due to concerns over its limited effectiveness, encouraging alternatives like nasal sprays and corticosteroids such as Flonase.
*
In March 2024, XHANCE (Fluticasone Propionate) nasal spray received FDA approval for treating chronic rhinosinusitis without nasal polyps in adults aged 18 and older. XHANCE is the first medication specifically approved for this condition, delivering corticosteroids directly to the nasal passages.
*
Key players advancing the rhinitis pipeline include Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma, AOBiome, Sanofi, Hanmi Pharmaceutical, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha Pharm, Siolta Therapeutics, Revelation Biosciences, Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology, Biomay AG, and others.
*
Promising pipeline candidates under development include REGN1908-1909, IRL201104, and additional therapies aimed at improving rhinitis treatment outcomes.
Rhinitis Overview:
Rhinitis is a condition characterized by nasal congestion, runny nose or post-nasal drip, sneezing, and itching. It can arise from multiple causes and is typically classified as either allergic or non-allergic. Allergic rhinitis, commonly known as hay fever, occurs when the immune system overreacts to harmless substances like pollen, mold, dust mites, pet dander, or other environmental triggers, causing histamine release and inflammation that leads to typical allergy symptoms. Non-allergic rhinitis, in contrast, is not triggered by allergens and may result from irritants such as smoke, weather changes, or infections. Rhinitis often coexists with or precedes sinusitis, which presents with facial pressure, reduced sense of smell, and discolored nasal discharge. Diagnosis and management by an ENT specialist are recommended, with treatment options tailored to the cause, including avoiding triggers, medications, or allergen immunotherapy such as allergy shots or sublingual tablets.
Download the Rhinitis sample report to know in detail about the Rhinitis treatment market @ https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Rhinitis Pipeline Analysis
The Rhinitis pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Rhinitis Market.
*
Categorizes Rhinitis therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Rhinitis drugs under development based on:
*
Stage of development
*
Rhinitis Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Rhinitis Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Rhinitis Licensing agreements
*
Funding and investment activities supporting future Rhinitis market advancement.
Unlock key insights into emerging Rhinitis therapies and market strategies here: https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Rhinitis Emerging Drugs
*
REGN1908-1909: Regeneron
REGN1908-1909 is a Phase III antibody therapy from Regeneron designed to target the Fel d 1 cat allergen and inhibit allergic reactions. Built using VelocImmune Registered technology, it is intended for the treatment of cat allergy-induced allergic rhinitis.
*
IRL201104: Revolo Biotherapeutics
IRL201104, based on a naturally occurring immune-regulatory protein, is designed to modulate the immune system and provide long-lasting allergy relief. It quickly decreases lung neutrophil infiltration following a bronchial challenge, although the effect is temporary. The therapy is currently being evaluated in Phase II trials for seasonal allergic rhinitis.
Rhinitis Pipeline Therapeutic Assessment
Rhinitis Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Rhinitis By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Rhinitis Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Rhinitis Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Rhinitis therapies and key Rhinitis companies: https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Rhinitis Current Treatment Patterns
4. Rhinitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Rhinitis Late-Stage Products (Phase-III)
7. Rhinitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Rhinitis Discontinued Products
13. Rhinitis Product Profiles
14. Rhinitis Key Companies
15. Rhinitis Key Products
16. Dormant and Discontinued Products
17. Rhinitis Unmet Needs
18. Rhinitis Future Perspectives
19. Rhinitis Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Rhinitis pipeline reports offerings: https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rhinitis-pipeline-2025-innovative-clinical-breakthroughs-led-by-35-global-leaders-delveinsight-highlighting-regeneron-revolo-biotherapeutics-anhui-palo-alto-pharmaceuticals-abdi-ibrahim-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rhinitis Pipeline 2025: Innovative Clinical Breakthroughs Led by 35+ Global Leaders, DelveInsight | Highlighting Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Abdi Ibrahim Pharma here
News-ID: 4176536 • Views: …
More Releases from ABNewswire
ANCA Vasculitis Pipeline 2025: Pioneering Clinical Progress Driven by 12+ Global …
DelveInsight's, "ANCA Vasculitis - Pipeline Insight, 2025," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The ANCA vasculitis (anti-neutrophil cytoplasmic antibody-associated vasculitis) market, a rare…
Autoimmune uveitis Market: Epidemiology, Therapies, Companies, DelveInsight | Ta …
The Autoimmune Uveitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Autoimmune Uveitis market size from 2020 to 2034. The Autoimmune Uveitis market report also covers current Autoimmune Uveitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Autoimmune Uveitis market.
Therapies for autoimmune uveitis, including YUTIQ, HUMIRA (Adalimumab), TRS01,…
Cutaneous lupus erythematosus Market: Epidemiology, Therapies, Companies, DelveI …
Cutaneous Lupus Erythematosus Treatment Market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Cutaneous Lupus Erythematosus market size from 2020 to 2034. The report also covers current Cutaneous Lupus Erythematosus treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Therapies for cutaneous lupus erythematosus, including Litifilimab, Daxdilimab, and others, are anticipated to drive…
Inflammatory Myositis Market: Epidemiology, Therapies, Companies, DelveInsight | …
Inflammatory myositis market report provides current treatment practices, emerging drug, market size and market share of the individual therapies, current and forecasted 7MM from 2020 to 2034. The report also covers current inflammatory myositis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Emerging therapies for inflammatory myositis, including Dazukibart (PF-06823859) and others, are anticipated to drive growth in…
More Releases for Rhinitis
Prominent Allergic Rhinitis Market Trend for 2025: Advancements In Treating Nasa …
Which drivers are expected to have the greatest impact on the over the allergic rhinitis market's growth?
Anticipated growth in the allergic rhinitis market is predicted to be driven by increasing levels of air pollution and the impact of climate change. The term air pollution denotes the existence of harmful substances in our planet's atmosphere, which can negatively impact human health, damage the environment, and reduce the air's quality. Climate change…
Allergic Rhinitis: A Comprehensive Overview
Allergic rhinitis, commonly known as hay fever, is a condition where an individual's immune system overreacts to allergens in the air. These allergens, which may include pollen, dust, or pet dander, trigger inflammation inside the nose, leading to symptoms like sneezing, a runny nose, itchy eyes, and congestion. While often associated with the spring and fall seasons due to pollen levels, allergic rhinitis can affect individuals year-round, depending on the…
Allergic Rhinitis Pipeline involves 32+ key companies continuously working towar …
DelveInsight's 'Allergic Rhinitis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Allergic Rhinitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Allergic Rhinitis pipeline domain.
Key Takeaways from the Allergic Rhinitis Pipeline Report
• DelveInsight's Allergic Rhinitis Pipeline analysis depicts a robust space with 32+ active players working to develop 32+ pipeline therapies…
Allergic Rhinitis Market 2018 by Seasonal, Perennial and Non-Allergic Rhinitis T …
The Allergic Rhinitis Treatment Market was valued at US $6.95 billion in the year 2018 and is estimated to reach US $9.66 billion by 2026, at a CAGR of 4.20%.
Allergic Rhinitis is inflammation caused inside the nose by allergen, also called as hay fever. Allergic Rhinitis develops when body’s immune system becomes sensitized and overreacts on exposure to allergens in the environment. It is mostly triggered by outdoor allergens like…
Allergic Rhinitis Market Growing CAGR of 7% with Key Type Seasonal, Perennial an …
Global Allergic Rhinitis Market to Provide Country Level Analysis of the Market with Respect to the Current Market Size and Future Growth prospect. And also Provide Insights about Factors Affecting the Market’s Growth.
Global Allergic Rhinitis Market - Scenario
The common name for allergic rhinitis is hay fever. It is diagnosed when symptoms appear which includes itchy nose, mouth, eyes, throat, skin, as well as other parts of the body; along with…
Allergic Rhinitis Market By Key Type Seasonal, Perennial and Non Allergic Rhinit …
Detail analysis of “Allergic Rhinitis Market” with Respect to Region Specific about Factors Affecting the market’s Growth and Various Analyses which Includes Price Analysis, Supply Chain Analysis, Porters Five Force Analysis on the Basis of Major Players Present in the Market - Forecast till 2022
Global Allergic Rhinitis Market - Scenario
The common name for allergic rhinitis is hay fever. It is diagnosed when symptoms appear which includes itchy nose, mouth, eyes,…
